Taysha Gene Therapies (TSHA) Q1 2025 earnings summary

Executive summary

• Achieved FDA alignment on pivotal trial design for TSHA-102 in Rett syndrome, expediting study initiation by eliminating the need for an end-of-phase meeting.

• Completed dosing in both low- and high-dose cohorts in phase I-II REVEAL trials, with 10 patients treated and no treatment-related serious adverse events or dose-limiting toxicities as of April 10, 2025.

• Functional gains observed in treated patients, including improvements in motor skills and communication, supporting the therapy's potential impact.

• TSHA-102 received multiple regulatory designations, including RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease from the FDA, and ILAP from the UK MHRA.

• Plans to present pivotal trial design, natural history analysis, and updated clinical data at the IRSF Rett Syndrome Scientific Meeting in June 2025.

Financial highlights

• Q1 2025 revenue was $2.3 million, down from $3.4 million in Q1 2024, recognized from Rett R&D activities under the Astellas agreement.

• Research and development expenses decreased to $15.6 million for Q1 2025 from $20.7 million in Q1 2024, mainly due to reduced GMP batch activities.

• General and administrative expenses increased to $8.2 million from $7.1 million year-over-year, driven by higher compensation and legal/professional fees.

• Net loss for Q1 2025 was $21.5 million ($0.08 per share), compared to $24.1 million ($0.10 per share) in Q1 2024.

• Cash and cash equivalents totaled $116.6 million as of March 31, 2025, expected to fund operations into Q4 2026.

Outlook and guidance

• Current cash resources are expected to fund operations and capital requirements into Q4 2026; additional capital will be required for continued R&D, manufacturing, and commercialization.

• IND amendment for pivotal Part B trial protocol and statistical analysis plan expected to be submitted in Q2 2025, with rapid trial initiation and potential dosing as early as late 2025 or early 2026.

• Plans to expand European footprint as resources allow, with regulatory groundwork established in the U.K. and Europe.

• Anticipates increased expenses as clinical development advances and as the company scales up for potential commercialization.